• CanSinoBIO joined the 27th DCVMN Annual General Meeting in Beijing on Sept. 22, 2026, outlining its long-term vaccine manufacturing strategy.
• Management flagged combination vaccines as a priority, seeking DCVMN partners for co-development to support stable supply in low- and middle-income markets.
• CanSinoBIO highlighted ongoing work on a Gates Foundation-backed VLP-Polio candidate, alongside an inhaled tuberculosis vaccine in Phase I in Indonesia.
• The company pointed to prior technology transfers in Indonesia, Mexico, Pakistan as a base for expanded joint R&D, manufacturing partnerships.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cansino Biologics Inc. published the original content used to generate this news brief on September 23, 2026, and is solely responsible for the information contained therein.